Dagher C, Huang A, Nasioudis D, Giuntoli II RL, Latif NA, Tanyi JL, Kim SH, Ko EM, Gysler SM, Martin LP Clinical Activity of Metronomic Cyclophosphamide and Bevacizumabwithor without Pembrolizumab in Recurrent Ovarian Cancer: A Single-Institution Retrospective Analysis. , SGO Annual Meeting, San Juan PR: 2026
Pavlatos E, Tate B, Nguyen A, Heller IS, Nasioudis D, Tanyi JL, Torigian DA, Rodriguez D, Domchek SM, Drapkin RI, Brown EJ, Mills GB, Simpkins F Increased immune activity in patients with high-grade serious ovarian cancer after combination PARPi + ATRi therapy. , AACR Annual Meeting, San Diego, CA: 2026
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek SM, Zhang L, Hu X Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. , bioRxiv: 2026,13:RP99225. doi: 10.7554/eLife.99225
Hu X, Huang J, Yuan J, Sun Y, Wang Y, Hu Z, Jiang J, Wang Z, Wang B, Long M, Maxwell KN, Fan Y, Tanyi JL, Montone KT, Li H, Kim SH, Nathanson KL, Rebbeck TR, Domchek SM, Vonderheide RH, Zhang L Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. , Cell Rep: 2026,45(2):116882. doi: 10.1016/j.celrep.2025
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. , Elife: 2026,13:RP99225. doi: 10.7554/eLife.99225
Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. , Mol Ther. : 2026,S1525-0016(26)00022-5. doi: 10.1016/j.ymthe.2026.01.021
Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. , Cell Rep Med. : 2025,6(9):102301. doi: 10.1016/j.xcrm.2025.102301
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ Jr, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. , .Cancer Cell: 2025,43(8):1568-1586.e10. doi: 10.1016
Gleason E, Pollie M, Satish S, Li S, Tanyi JL Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report. , Gynecol Oncol Rep: 2025,60:101816. doi: 10.1016/j.gore.2025.101816
Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ. Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations , Int J Surg Pathol: 2025,33(4):921-927. doi: 10.1177/10668969241291890
